Pharmaceutical Executive-03-12-2009

The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?

Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own.